Introduction
Ketamine therapy produces rapid but variable antidepressant effects that fluctuate between treatment sessions, making systematic outcome measurement more important than for conventional antidepressants with gradual onset and sustained effects. Unlike SSRIs -- where a clinician might assess response at 4-week intervals -- ketamine's rapid onset (hours to days), relatively short duration of acute effect (days to weeks), and dose-session-dependent trajectory demand frequent, structured assessment.
Without validated outcome measures, clinicians risk making dosing and frequency decisions based on subjective impressions, patient report biased by recency effects, or clinical intuition that -- while valuable -- lacks the precision needed for optimizing a treatment with this pharmacokinetic profile.
This guide covers the selection, administration, interpretation, and clinical application of outcome measures in ketamine therapy practice.
Primary Depression Scales
PHQ-9 (Patient Health Questionnaire-9)
The PHQ-9 is the most widely used depression screening and outcome tracking instrument in clinical practice. Its advantages for ketamine therapy include brevity (9 items, typically completed in <3 minutes), free availability (no licensing fees), patient self-administration, and familiarity to most clinicians and patients.
Scoring and interpretation:
- 0-4: Minimal or no depression
- 5-9: Mild depression
- 10-14: Moderate depression
- 15-19: Moderately severe depression
- 20-27: Severe depression
Response and remission thresholds:
- Response: 50% or greater reduction from baseline score
- Remission: Score <5
Limitations for ketamine practice: The PHQ-9 assesses symptoms over the preceding two weeks, which may not capture the rapid fluctuations characteristic of ketamine response. Some clinicians modify the time frame to "since your last treatment" for within-course tracking, though this deviates from validated administration.
MADRS (Montgomery-Asberg Depression Rating Scale)
The MADRS is a 10-item clinician-administered scale that is the most commonly used primary outcome measure in ketamine clinical trials. It has several advantages for ketamine research and practice: greater sensitivity to change than the PHQ-9, clinician administration allowing for clinical judgment in scoring, and established use in the ketamine literature facilitating comparison with published trial data.
Scoring and interpretation:
- 0-6: Normal / symptom absent
- 7-19: Mild depression
- 20-34: Moderate depression
- 35-60: Severe depression
Response and remission thresholds:
- Response: 50% or greater reduction from baseline score
- Remission: Score <10
Limitations: Clinician administration requires training and takes 15-20 minutes. This may be impractical for high-volume practices. The MADRS is copyrighted, though generally available for clinical use without licensing fees.
QIDS-SR (Quick Inventory of Depressive Symptomatology - Self Report)
The QIDS-SR provides a balance between the brevity of the PHQ-9 and the clinical depth of the MADRS. This 16-item self-report scale was designed to map onto DSM diagnostic criteria and is scored on a 0-27 scale.
Scoring:
- 0-5: No depression
- 6-10: Mild
- 11-15: Moderate
- 16-20: Severe
- 21-27: Very severe
Response and remission: Response is a 50% or greater reduction; remission is a score <6.
Supplementary Scales
Columbia Suicide Severity Rating Scale (C-SSRS)
Given ketamine's documented rapid antisuicidal effects and the high-acuity population frequently treated, the C-SSRS should be administered at baseline and at regular intervals during treatment. This clinician-administered scale classifies suicidal ideation on a 1-5 severity scale and documents suicidal behavior. Changes in C-SSRS ratings provide critical safety data and may influence treatment urgency and frequency.
Beck Scale for Suicidal Ideation (BSS)
An alternative to the C-SSRS, the BSS is a 21-item self-report measure that quantifies the intensity of suicidal ideation. It provides a continuous score that may be more sensitive to change than the categorical C-SSRS classifications.
Visual Analog Scale for Dissociation (VAS-D) and CADSS
The Clinician-Administered Dissociative States Scale (CADSS) is a 23-item measure of dissociative symptoms administered during or immediately after ketamine treatment. While not an outcome measure per se, dissociation intensity has been studied as a potential predictor of antidepressant response. Tracking CADSS or VAS-D scores alongside depression measures may help identify optimal dosing for individual patients.
Pain Scales
For patients receiving ketamine for chronic pain indications, the Numeric Rating Scale (NRS, 0-10), Brief Pain Inventory (BPI), or condition-specific measures (e.g., the Neuropathic Pain Symptom Inventory) should be administered alongside depression scales.
Anxiety Measures
The GAD-7 (Generalized Anxiety Disorder-7) is a brief self-report measure that captures anxiety symptoms relevant to many ketamine patients. Given the high comorbidity of anxiety and depression in the ketamine-treated population, tracking anxiety alongside depression provides a more complete picture of treatment response.
Assessment Frequency
Induction Phase (Typically 2-3 Weeks)
During the initial series of ketamine treatments, scales should be administered at every treatment visit -- typically before each session. This provides a session-by-session response trajectory that informs within-course dosing decisions.
Recommended pre-session assessments:
- PHQ-9 or QIDS-SR (self-administered in the waiting room)
- C-SSRS (for patients with baseline suicidal ideation)
- GAD-7 (for patients with comorbid anxiety)
- Pain NRS (for pain patients)
At the midpoint of induction (after session 3 of a 6-session course):
- Full MADRS (if used as primary clinician-rated measure)
- Clinical decision point: assess whether dose adjustment is warranted based on trajectory
At the end of induction:
- All baseline measures repeated
- Formal determination of response or remission status
- Treatment planning decision: proceed to maintenance, extend induction, or discontinue
Maintenance Phase
During maintenance treatment, assessment frequency can be reduced but should remain systematic:
- PHQ-9 or QIDS-SR at every maintenance session
- Full MADRS every 4-6 weeks or at each dose/frequency change
- C-SSRS as clinically indicated
- Functional measures (work productivity, social engagement) quarterly
Between Sessions
For patients on at-home sublingual or oral ketamine, brief mood tracking between sessions provides valuable data. Patients can be instructed to complete daily or weekly PHQ-2 (the 2-item screening version) via paper logs or digital health platforms, capturing the trajectory of mood between treatment days.
Interpreting Response Patterns
Classic Responders
The typical ketamine responder shows partial improvement after 1-2 treatments, progressive improvement through treatment 4-6, and achieves response (50% or greater score reduction) by the end of induction. This pattern accounts for approximately 50-70% of responders in clinical trials.
Rapid Responders
Some patients demonstrate dramatic improvement within 24 hours of the first infusion, with PHQ-9 or MADRS scores dropping by 50% or more after a single treatment. While encouraging, rapid response does not guarantee sustained benefit -- these patients may also show rapid relapse between sessions.
Delayed Responders
A subset of patients shows minimal improvement during the standard 6-session induction but achieves response with 2-4 additional treatments. Clinicians should consider extending induction (up to 8-10 sessions) before declaring treatment failure, particularly for patients showing a positive trajectory (even if modest) during the initial course.
Non-Responders
Patients showing no meaningful improvement (defined as <25% reduction in primary outcome measure) after 6-8 treatments are unlikely to respond to continued treatment at the current dose and route. Clinical options include dose escalation, route change (e.g., switching from sublingual to IV), or treatment discontinuation.
Data-Driven Dosing Decisions
Systematic outcome data enables evidence-based dosing adjustments:
Dose escalation indicators:
- Partial response (<50% score reduction) after 3-4 treatments at current dose
- Response that plateaus before reaching remission
- Good tolerability with minimal side effects at current dose
Frequency adjustment indicators:
- Consistent pattern of symptom return at a specific interval after treatment (e.g., mood consistently worsening at day 5 post-infusion, suggesting a treatment interval of <7 days is needed during maintenance)
- Sustained remission scores for 3 or more consecutive sessions, suggesting interval extension is feasible
Treatment continuation vs. discontinuation:
- Score data demonstrating sustained response over 3+ months supports continuation
- Failure to achieve meaningful response after adequate trials of dose and route supports discontinuation
Documentation and Quality Assurance
Standardized Score Tracking
Maintain a score tracking log for each patient, documenting:
- Date, treatment number, and dose for each assessment
- Raw scores on all administered instruments
- Calculated percent change from baseline
- Response/remission status at each decision point
- Any clinical decisions triggered by score data (dose changes, frequency changes, discontinuation)
This documentation serves both clinical and medicolegal purposes, demonstrating evidence-based treatment management.
Practice-Level Quality Metrics
Aggregate outcome data across patients enables practice quality monitoring:
- Overall response rate (percentage of patients achieving 50% or greater reduction)
- Remission rate
- Mean percent improvement from baseline
- Time to response (number of sessions to achieve response)
- Dropout rate and reasons for discontinuation
These metrics support continuous quality improvement and provide data for clinical program evaluation.
Conclusion
Systematic outcome tracking using validated instruments transforms ketamine therapy from an art based on clinical impression into a data-driven practice with defensible, reproducible decision-making. The PHQ-9 and MADRS serve as primary depression outcome measures, supplemented by suicide risk scales, anxiety measures, and pain instruments as clinically indicated. Assessments should be conducted at every treatment session during induction and at each maintenance session thereafter. The resulting data enables individualized dosing, evidence-based continuation decisions, and practice-level quality assurance.
References
- Kroenke K, et al. The PHQ-9: Validity of a Brief Depression Severity Measure. J Gen Intern Med. 2001;16(9):606-613 — Validation of the PHQ-9
- Montgomery SA, Asberg M. A New Depression Scale Designed to be Sensitive to Change. Br J Psychiatry. 1979;134:382-389 — Original MADRS validation
- Rush AJ, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS): Psychometric Evaluation in Patients with Chronic Major Depression. Biol Psychiatry. 2003;54(5):573-583 — QIDS-SR validation
- Posner K, et al. The Columbia-Suicide Severity Rating Scale. Am J Psychiatry. 2011;168(12):1266-1277 — C-SSRS development and validation
- Murrough JW, et al. Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression. Am J Psychiatry. 2013;170(10):1134-1142 — Use of MADRS as primary ketamine outcome measure
- National Institute of Mental Health: Depression Assessment Tools — NIMH clinical assessment resources
- Ballard ED, et al. Improvement in Suicidal Ideation After Ketamine Infusion. Psychopharmacology. 2014;231(24):4701-4707 — Ketamine effects on suicidal ideation measurement
Share